Phospholipid-mimic oxaliplatin prodrug liposome for treatment of the metastatic triple negative breast cancer?

Biomaterials Science Pub Date: 2017-03-31 DOI: 10.1039/C7BM00058H

Abstract

A phospholipid-mimic oxaliplatin prodrug (Oxalipid) was synthesized, which could self-assemble into a liposomal nanostructure with a drug loading ratio as high as 27 wt%. Compared to free oxaliplatin, the resulting Oxalipid liposome displayed elongated blood circulation, increased tumor accumulation and improved anticancer efficacy against the metastatic triple negative breast cancer (TNBC).

Graphical abstract: Phospholipid-mimic oxaliplatin prodrug liposome for treatment of the metastatic triple negative breast cancer
Recommended Literature